Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
JAK2 3717 CT-1578 CHEMBL3544962 inhibitor ChemblInteractions
JAK2 3717 BARICITINIB CHEMBL2105759 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 XL-019 CHEMBL3545328 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, TTD
JAK2 3717 TOFACITINIB CHEMBL221959 antagonist, inhibitor DrugBank 10592235
JAK2 3717 BMS-911543 CHEMBL3545215 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 CHEMBL3116050 CHEMBL3116050 inhibitor GuideToPharmacologyInteractions
JAK2 3717 FILGOTINIB CHEMBL3301607 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions
JAK2 3717 ITACITINIB CHEMBL3622820 inhibitor GuideToPharmacologyInteractions
JAK2 3717 PAROXETINE CHEMBL490 inhibitor GuideToPharmacologyInteractions
JAK2 3717 NS-018 CHEMBL3545217 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 PEFICITINIB CHEMBL3137308 inhibitor ChemblInteractions
JAK2 3717 LS-104 CHEMBL3544997 inhibitor ChemblInteractions
JAK2 3717 TOFACITINIB CITRATE CHEMBL2103743 inhibitor ChemblInteractions
JAK2 3717 CHEMBL500779 CHEMBL500779 DrugBank 10592235
JAK2 3717 CHEMBL2062804 CHEMBL2062804 inhibitor GuideToPharmacologyInteractions
JAK2 3717 Cerdulatinib CHEMBL3545284 inhibitor GuideToPharmacologyInteractions
JAK2 3717 DECERNOTINIB CHEMBL3039513 inhibitor GuideToPharmacologyInteractions
JAK2 3717 MOMELOTINIB CHEMBL1078178 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions 24398328, 21926964
JAK2 3717 PACRITINIB CHEMBL2035187 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 CHEMBL1213492 CHEMBL1213492 inhibitor TTD
JAK2 3717 PIBOSEROD CHEMBL356359 inhibitor TTD
JAK2 3717 RP-6530 CHEMBL3545141 CKB
JAK2 3717 CHEMBL21156 CHEMBL21156 inhibitor CKB, GuideToPharmacologyInteractions, DrugBank 10592235, 22916261
JAK2 3717 RUXOLITINIB CHEMBL1789941 inhibitor MyCancerGenome, DrugBank, GuideToPharmacologyInteractions, OncoKB, MyCancerGenomeClinicalTrial, TdgClinicalTrial, CGI, CKB, DoCM 23514013, 23061804, 22899477, 25207766, 23630205, 22875628, 25515960, 23400675, 25260694, 24398328, 22271575, 21926964, 24251790, 21393331, 26472029, 20631743, 21689158, 22422826, 15781101, 16293597, 21120162, 22818858, 16081687, 20339092, 22829971, 22041374, 24986690, 25157968, 24404189, 18394554, 23115274, 22571758, 16709929, 19287384, 19470474, 22368270, 22955920, 18805579, 20585391
JAK2 3717 FEDRATINIB CHEMBL1287853 inhibitor MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CIViC, TTD 24398328, 21926964, 18394554
JAK2 3717 TG-02 CHEMBL1944698 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 AC-430 CHEMBL3545241 inhibitor TdgClinicalTrial, ChemblInteractions
JAK2 3717 RUXOLITINIB PHOSPHATE CHEMBL1795071 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial, TTD
JAK2 3717 ENMD-2076 CHEMBL482968 TdgClinicalTrial
JAK2 3717 NVP-AUY922 CHEMBL252164 CKB 24398328
JAK2 3717 PACLITAXEL CHEMBL428647 CKB 27075627
JAK2 3717 AT-9283 CHEMBL495727 inhibitor TALC, MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 CHEMBL480411 CHEMBL480411 DrugBank 10592235
JAK2 3717 GANDOTINIB CHEMBL2107823 inhibitor MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions
JAK2 3717 RGB-286638 CHEMBL3545083 inhibitor GuideToPharmacologyInteractions
JAK2 3717 GO-6976 CHEMBL302449 CKB 16956345
JAK2 3717 DACTOLISIB CHEMBL1879463 CKB 24251790
JAK2 3717 SGI-1776 CHEMBL1952329 CKB 26472029
JAK2 3717 PEMBROLIZUMAB CHEMBL3137343 CKB, CIViC 27433843
JAK2 3717 ZSTK-474 CHEMBL586701 CKB 24251790
JAK2 3717 PICTILISIB CHEMBL521851 CKB 24251790
JAK2 3717 AZD-1480 CHEMBL1231124 inhibitor MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions 21926964
JAK2 3717 LESTAURTINIB CHEMBL603469 inhibitor TdgClinicalTrial, CKB, ChemblInteractions 21926964
JAK2 3717 IMATINIB CHEMBL941 CKB 21224473
JAK2 3717 AZD-1208 CHEMBL3545423 CKB 26472029

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
JAK2 rs12343867 CC Tumor necrosis factor alpha efficacy yes When comparing responders vs. non-responders. However, no significant association was seen when comparing the CT vs TT genotype, or the CC + CT vs TT genotype. Additionally, no association was seen for any genotype when considering responders vs. non- and partial-responders. Genotype CC is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative as compared to genotype TT. 28139755 1448604190